BioXcel Therapeutics strengthens cash position to advance SERENITY trial
BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on ...
BioXcel announces FDA closed inspection of TRANQUILITY II Phase 3 trial site
BioXcel Therapeutics (BTAI) announced that the U.S. Food and Drug Administration has concluded that the inspection of a single site in its ...
Nasdaq5d
BioXcel Therapeutics Announces Strong Cash Position to Advance SERENITY At-Home Trial for IGALMI® Label Expansion
BioXcel Therapeutics, Inc. announced it has raised $14 million in equity financing, providing the company with approximately $35 million in cash to support its pivotal Phase 3 SERENITY At-Home ...
MarketWatch8d
BioXcel Therapeutics Climbs After Enrollment Update in Drug Trial
Shares of BioXcel Therapeutics rose after the company said it has reached 33% enrollment in a trial of a treatment for agitation associated with bipolar disorders or schizophrenia. The ...